Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.

Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C, Watson KE, Willey VJ, Stanek EJ.

Circulation. 2005 Feb 1;111(4):488-93.

2.

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C; European Consensus Panel on HDL-C.

Curr Med Res Opin. 2004 Aug;20(8):1253-68. Review.

PMID:
15324528
3.
4.
5.
6.

Evaluation and treatment of lipid disorders in women.

Zelis R.

Curr Womens Health Rep. 2003 Apr;3(2):97-103. Review.

PMID:
12628078
7.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
8.

Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.

Shepherd J, Betteridge J, Van Gaal L; European Consensus Panel.

Curr Med Res Opin. 2005 May;21(5):665-82. Review.

PMID:
15969866
9.

Present-day uses of niacin: effects on lipid and non-lipid parameters.

Sanyal S, Karas RH, Kuvin JT.

Expert Opin Pharmacother. 2007 Aug;8(11):1711-7. Review.

PMID:
17685887
10.

Applicability of cholesterol-lowering primary prevention trials to a general population: the framingham heart study.

Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, Massaro J, Silbershatz H, Wilson PW.

Arch Intern Med. 2001 Apr 9;161(7):949-54. Review.

PMID:
11295957
11.

The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.

Ito MK.

Ann Pharmacother. 2004 Feb;38(2):277-85. Epub 2003 Dec 30. Review.

PMID:
14742767
12.
13.

Impact of dyslipidemia in end-stage renal disease.

Prichard SS.

J Am Soc Nephrol. 2003 Sep;14(9 Suppl 4):S315-20. Review.

15.

Lipid disorders in type 2 diabetes.

Braun LT.

Nurs Clin North Am. 2001 Jun;36(2):291-302, vii. Review.

PMID:
11382564
17.

Using lipid-lowering agents effectively. When diet is not enough.

Scott D, Kurenitz M.

Postgrad Med. 1990 Jun;87(8):171-6, 179-81, 186. Review.

PMID:
2189126
18.

Past, present, and future standards for management of dyslipidemia.

LaRosa JC, Gotto AM Jr.

Am J Med. 2004 Mar 22;116 Suppl 6A:3S-8S. Review.

PMID:
15050186
19.
20.

Dyslipidemia and coronary heart disease: management issues from Indian perspective.

Gambhir DS, Gambhir JK, Sudha R.

Indian Heart J. 2000 Sep-Oct;52(5):515-6, 617. Review. No abstract available.

PMID:
11256772

Supplemental Content

Support Center